Twelve-Month Results From the First-in-China Prospective, Multi-Center, Randomized, Controlled Study of the FREEWAY Paclitaxel-Coated Balloon for Femoropopliteal Treatment

Bihui Zhang, Min Yang, Tao He, Xuan Li, Jianping Gu, Xiaoming Zhang, Xiangchen Dai, Xuedong Li, Xinwu Lu, Dehai Lang, Hongyao Hu, Xueming Chen, Baozhong Yang, Hongbin Gu, Xiwei Zhang, Yinghua ZouFrontiers in Cardiovascular Medicine 2021 · DOI

TL;DR

This study demonstrates that the FREEWAY paclitaxel-coated balloon significantly reduces the need for repeat procedures (clinically-driven target lesion revascularization) in Chinese patients with femoropopliteal artery disease compared to standard uncoated balloons, while maintaining similar safety profiles. This provides crucial evidence for the efficacy and safety of this specific drug-coated balloon technology in an Asian population.

What Problem Does This Paper Address?

Peripheral artery disease (PAD) affecting the femoropopliteal segment of the leg is a common and debilitating condition. While endovascular treatments like angioplasty are widely used, restenosis (re-narrowing of the artery) and the need for subsequent interventions remain significant challenges. Paclitaxel-coated balloons (DCBs) have emerged as a promising therapeutic option to reduce restenosis by delivering a drug to the vessel wall. However, the efficacy and safety of specific DCB devices, like the FREEWAY balloon, needed to be evaluated in diverse patient populations, particularly in China, where treatment responses might differ due to genetic or lifestyle factors. This study addresses the gap in understanding the performance of the FREEWAY DCB in Chinese patients with femoropopliteal lesions.

Methods

This was a prospective, multi-center, randomized controlled trial (RCT) named the FREEWAY-CHINA study. 311 patients with symptomatic lower limb ischemia (Rutherford categories 2-5) and femoropopliteal lesions were recruited from 14 Chinese hospitals. Participants were randomly assigned in a 1:1 ratio to receive endovascular treatment with either the FREEWAY paclitaxel-coated balloon or a standard uncoated balloon (control).

The primary endpoint was the rate of clinically-driven target lesion revascularization (CD-TLR) at 6 months. CD-TLR was defined as an increase in Rutherford grade or a Doppler ultrasound showing ≥ 70% diameter stenosis, necessitating repeat intervention. Secondary endpoints included device and technical success rates, changes in ankle-brachial indexes (ABIs), Rutherford category, primary and secondary patency rates, and the incidence of severe adverse effects and CD-TLR at 12 months.

Datasets

Not discussed in the paper. The study involved patient data collected from 14 clinical centers in China.

Key Insights and Ideas

  • Ethnic Specificity Matters: The study highlights the importance of evaluating medical devices in specific ethnic populations. Previous studies on DCBs were largely conducted in Caucasian populations, and this trial provides crucial data for Chinese patients.
  • Drug-Coated Balloons Offer a Clear Advantage: The results strongly suggest that paclitaxel-coated balloons, specifically the FREEWAY device, are superior to standard balloons in preventing the need for repeat interventions in femoropopliteal lesions.
  • Safety Profile is Comparable: Despite concerns sometimes raised about paclitaxel safety, this study found no significant differences in major adverse events, including death and major amputation, between the FREEWAY group and the control group, reinforcing its safety in this context.
  • Beyond Restenosis: While the primary focus was on reducing revascularization, the study also looked at other indicators of treatment success like patency rates and ABI improvements, finding no significant differences, suggesting that the main benefit of the DCB lies in preventing restenosis-driven reinterventions.

Key Results

  • Reduced Revascularization: The 6-month CD-TLR rate was significantly lower in the FREEWAY group (2.6%) compared to the control group (11.7%) (P = 0.001). This advantage was maintained at 12 months, with rates of 2.7% for FREEWAY versus 13.2% for the control group (P = 0.0005).
  • Similar Safety: Major adverse events, including all-cause death, revascularization, and major amputation, occurred at similar rates in both groups at 1, 6, and 12 months. Device-associated severe adverse effects also did not differ significantly.
  • No Difference in Other Efficacy Measures: While the FREEWAY group showed a trend towards higher primary patency at 6 months, this difference was not statistically significant. Secondary patency rates and changes in ABI and Rutherford categories were comparable between the two groups.
  • Procedural Characteristics: The FREEWAY group had a higher proportion of patients with multiple lesions and required more frequent second balloon dilations. Bailout stenting was less frequent in the FREEWAY group.

Limitations and Future Work

The authors acknowledge several limitations:

  • Endpoint Evaluation: The evaluation of endpoints was not performed by independent core laboratories, which could introduce bias.
  • Patient Selection: Patients with severe calcification and very long lesions were excluded, limiting the generalizability of the findings to these more complex cases.
  • Long-Term Data: While 12-month data is presented, longer-term follow-up is needed to definitively assess the sustained safety and efficacy of the FREEWAY balloon in Chinese patients.

Future work could focus on extending follow-up periods to confirm long-term outcomes and potentially investigate the FREEWAY balloon in more complex lesion subsets. Further research into the impact of ethnicity on paclitaxel response could also be valuable.

Summary updated

Abstract

<b>Background:</b> Several paclitaxel-coated balloons have been proved to provide better efficacy results than uncoated balloons in femoropopliteal lesions. But the efficacy and safety of FREEWAY balloons have not been investigated in Chinese patients. This study aimed to evaluate the efficacy and safety performance of FREEWAY paclitaxel-coated balloons vs. uncoated balloons in Chinese femoropopliteal artery lesions. <b>Methods:</b> In this prospective multi-center randomized controlled FREEWAY-CHINA study, 311 patients with symptomatic lower limb ischemia (Rutherford category 2-5) and femoropopliteal lesions of 14 Chinese centers were randomly assigned in a 1:1 ratio to endovascular treatment with either FREEWAY paclitaxel-coated balloons or uncoated balloons (control). The primary endpoint was the 6-month clinically-driven target lesion revascularization (CD-TLR) rate. Secondary endpoints included the device and technical success rate, the ankle-brachial indexes (ABIs), Rutherford category change, the 6-month primary and secondary patency rates, severe adverse effects, and the 12-month CD-TLR rate. <b>Results:</b> The two groups were comparable in terms of their demographic and lesion characteristics. Patients' mean age was 70 years, and 70% were men. The mean lesion length was 71 mm. The 6-month CD-TLR rate was 2.6% in the FREEWAY group and 11.7% in the control group (<i>P</i> = 0.001). The 12-month CD-TLR rate was 2.7% in the FREEWAY group and 13.2% in the control group (<i>P</i> = 0.0005). Other endpoints, including patency rates, major adverse events, and ABI or Rutherford change, did not differ between the two groups. <b>Conclusion:</b> The FREEWAY balloon resulted in an effective decrease in CD-TLR rates and had similar safety results compared to the uncoated balloon in Chinese femoropopliteal artery patients at the 12-month follow-up appointment.
BibTeX
@inproceedings{zhang2021twelve,
  author = {Bihui Zhang and Min Yang and Tao He and Xuan Li and Jianping Gu and Xiaoming Zhang and Xiangchen Dai and Xuedong Li and Xinwu Lu and Dehai Lang and Hongyao Hu and Xueming Chen and Baozhong Yang and Hongbin Gu and Xiwei Zhang and Yinghua Zou},
  title = {{Twelve-Month Results From the First-in-China Prospective, Multi-Center, Randomized, Controlled Study of the FREEWAY Paclitaxel-Coated Balloon for Femoropopliteal Treatment}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.686267},
}
Figure